Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Nuertingen – page 10

961 clinical trials in Nuertingen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Nuertingen at a glance
961
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

961 trials in Nuertingen

Open in trial search

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

FWY003 in Geographic Atrophy Secondary to Age-Related Macular Degeneration in Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:FWY003 tosilate
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Nuertingen

What the registry says about research in the country

01 Neoplasms

Clinical trial research in Nürtingen is focused on neoplasms, with studies centered on improving treatment options and patient outcomes in cancer care.

  • Focus on prostate cancer and renal cell carcinoma
  • Evaluating new approaches for metastatic castration-sensitive prostate cancer
  • Testing combination treatments for previously untreated locally advanced unresectable or metastatic renal cell carcinoma
  • Assessing both treatment effectiveness and tolerability

These studies aim to refine cancer therapy, with an emphasis on balancing disease control, safety, and patient comfort.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.